Recombinant collagen products developed by Jiangsu Hernrrie Biomedical Technology, located in the Taizhou Medical High-tech Zone, Taizhou city, East China's Jiangsu province, have been approved for Class II medical device registration.
This marks the company's significant breakthroughs in functional protein raw materials and medical device markets.
Recombinant type III humanized collagen has shown broad applications prospects in fields such as medical beauty, wound repair and tissue regeneration due to its unique repair and regeneration ability, high purity and low immunogenicity.
In the future, it is also expected to play a role in clinical applications such as surgical sutures, hemostatic fibers, artificial skin, artificial blood vessels, corneas and nerve repair materials.
Synthetic biology is one of the cutting-edge fields in the development of biotechnology and Hernrrie has applied synthetic biology technology to medical devices, biomaterials, medical beauty, big health sector and other fields.
A recombinant collagen wound dressing product from Jiangsu Hernrrie Biomedical Technology. [Photo/WeChat account: weigg6666]